Jennifer Eng-Wong,Whitney Kirschbrown,Tarik Khan,Jasper Lin,Sreedhara Alavattam,Amit Garg,Sarah Heeson,Tanja Badovinac-Crnjevic,Christine Wurth
申请号：
US15872648
公开号：
US20180296470A1
申请日:
2018.01.16
申请国别(地区):
US
年份:
2018
代理人:
摘要：
Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.
